The Australian Immunisation Handbook 10th Edition

4.17 Rotavirus

Page last updated: 08 April 2016

4.17.1 Virology

Rotaviruses are non-enveloped RNA viruses that are classified according to the two surface proteins they contain: VP7, the ‘G’ glycoprotein, and VP4, the protease-cleaved ‘P’ protein. The G and P proteins are targets for the neutralising antibodies that contribute to protection against reinfection and disease.1,2 The two gene segments that encode these proteins can segregate independently, and a binary typing system, consisting of both P and G types, has been developed. Rotavirus strains are most commonly referred to by their G serotype, with G1, G2, G3, G4 and G9 accounting for around 90% of serotypes, both globally and in Australia.3,4 The most common P types found in combination with these G types are P1A[8] (found with all common G types except G2) and P1B[4], usually found in combination with G2.5

4.17.2 Clinical features

Rotavirus is the predominant agent of severe dehydrating gastroenteritis in infants and young children in both developed and developing countries.1,2 The spectrum of rotavirus infection ranges from asymptomatic infection, to mild, watery diarrhoea of limited duration, to severe dehydrating diarrhoea with vomiting, fever, electrolyte imbalance, shock and death. Rotavirus infections are often more severe than other common causes of diarrhoea, and are more likely to result in dehydration and hospitalisation.1,6 The incubation period is 1 to 3 days, after which illness can begin abruptly, with vomiting often preceding the onset of diarrhoea.6 Up to one-third of patients have a temperature of >39°C in the first few days of illness. Symptoms generally resolve in 3 to 7 days.

4.17.3 Epidemiology

Rotaviruses are shed in high concentrations in the stools of infected children and are transmitted by the faecal–oral route, both through close person-to-person contact and via fomites.7 In some instances, rotaviruses might also be transmitted by other modes, such as faecally contaminated food, water and respiratory droplets.6,8

Infection in early childhood is thought to be universal. Although individuals can be infected several times during their lives, the first infection, typically between 3 and 36 months of age, is most likely to cause severe diarrhoea and dehydration.9,10 The degree of protection following natural infection varies. After a single natural infection, 40% of children are protected against any subsequent infection with rotavirus, 75% are protected against diarrhoea from a subsequent rotavirus infection, and 88% are protected against severe diarrhoea.10 Repeat infections provide even greater protection. Prior to the introduction of rotavirus vaccines in Australia, the best available estimates were that approximately 10 000 hospitalisations due to rotavirus occurred each year in children <5 years of age,11 equating to around half the hospitalisations for acute gastroenteritis in this age group11,12 and affecting 3.8% of all children (1 in 27) by the age of 5 years. In addition to hospitalisations, an estimated 115 000 children <5 years of age visited a GP, and 22 000 children required an emergency department visit due to rotavirus.11,13 On average, there was 1 death attributed to rotavirus each year in Australia, but this is likely to be a minimum estimate.13 Following the introduction of rotavirus vaccines to the NIP in 2007, substantial reductions (>70%) in both rotavirus-specific and all-cause hospital presentations for gastroenteritis have been reported (Figure 4.17.1).14-17 Emergency department visits for acute gastroenteritis have also declined, as have rotavirus notifications.18,19

In temperate Australia, rotavirus infections follow a seasonal pattern, with the peak incidence being in mid to late winter. In the northern tropical and arid regions, there is no consistent seasonal pattern – disease peaks are unpredictable20 and widespread epidemics cause severe strain on healthcare services.21,22 Overall, Indigenous infants and children are hospitalised with rotavirus gastroenteritis about 3 to 5 times more commonly than their non-Indigenous peers, are younger at hospitalisation, and have a longer duration of stay (an average of 5 days, compared with 2 days for non-Indigenous infants).12,20,21,23

Immunocompromised children and adults, such as those with congenital immunodeficiency, or post haematopoietic or solid organ transplantation, are at increased risk of severe, prolonged and even fatal rotavirus gastroenteritis.1,24,25 Rotavirus is an important cause of nosocomial gastroenteritis,26-30 and can also cause disease in adults, especially among those caring for children and those residing in aged care facilities.1,31,32

Figure 4.17.1: Rotavirus-coded hospitalisations per month, Australia, 2001 to 201017

4.17.1: Rotavirus-coded hospitalisations per month, Australia, 2001 to 201017

4.17.4 Vaccines

Two oral rotavirus vaccines are available in Australia, and their efficacy and safety in the prevention of rotavirus gastroenteritis have been extensively evaluated.33-39 Both are live attenuated vaccines administered orally to infants, but the component vaccine viruses differ. The human rotavirus vaccine, Rotarix (GlaxoSmithKline), is a live attenuated vaccine containing one strain of attenuated human rotavirus (G1P1A[8] strain). Rotarix protects against non-G1 serotypes on the basis of other shared epitopes. A pentavalent vaccine, RotaTeq (CSL Limited/Merck & Co Inc), contains five human–bovine rotavirus reassortants with the human serotypes G1, G2, G3, G4 and P1A[8] and the bovine serotypes G6 and P7.

In middle- and high-income countries, a course of vaccination with either Rotarix or RotaTeq prevents rotavirus gastroenteritis of any severity in approximately 70% of recipients and prevents severe rotavirus gastroenteritis and rotavirus hospitalisation for 85 to 100% of recipients for up to 3 years.33,34,40,41 Vaccination is also highly effective in preventing emergency department and clinic/GP visits.33,40 Overall, in pre-market clinical trials, rotavirus vaccination prevented around half (42–58%) of hospital admissions for acute gastroenteritis of any cause in young children, suggesting that rotavirus is responsible for more gastroenteritis than detected using routine testing and admission practices.33,34,40 post-marketing studies in the United States and Australia have confirmed high vaccine effectiveness and impressive reductions in both rotavirus-coded and all-cause gastroenteritis hospitalisations.15,19,42-46 Reductions have also been observed in age groups not eligible for vaccination, suggesting that herd protective effects are also likely to exist for rotavirus vaccines.15,19,45

Although more modest estimates of efficacy have been reported in resource-poor settings,36-38,47 post-marketing evaluation in the middle income countries Mexico and Brazil have revealed substantial reductions in diarrhoea-related mortality since vaccine introduction.48,49 Studies of Rotarix during consecutive epidemics in Central Australia gave generally lower and wide-ranging vaccine effectiveness estimates, which require further investigation.46,50 Considering the uniqueness of the remote Australian setting, these results should not be extrapolated to elsewhere in Australia, where the weight of evidence indicates a substantial reduction in the burden of rotavirus disease following vaccine introduction. To date, there has been no convincing evidence of important differences between the two vaccines with regard to protective efficacy against different serotypes.33,34,39

RotaShield, a tetravalent rhesus-reassortant vaccine, which was licensed in the United States (but not elsewhere) in 1998–99, was subsequently associated with intussusception (IS, an uncommon form of bowel obstruction in young children) in approximately 1 in 10 000 vaccine recipients.51 The pathogenesis of RotaShield-associated IS has not been determined. The greatest risk of IS occurred within 3 to 14 days after the 1st dose, with a smaller risk after the 2nd dose.51,52 There is evidence suggesting that when the 1st dose of RotaShield was given at >3 months of age, the risk of IS was increased.52 The current rotavirus vaccines (Rotarix and RotaTeq) differ in composition to RotaShield, which was more reactogenic.53-55 The large-scale safety studies of Rotarix and RotaTeq included approximately 140 000 infants, and found the risk of IS in vaccine recipients to be similar to that of placebo recipients, and less than that estimated for RotaShield.33,34 A meta-analysis of clinical trial data also did not find evidence of an increased risk of IS among vaccine recipients.39 The clinical trials of Rotarix and RotaTeq limited administration of the 1st dose of vaccine to infants under 14 and 12 weeks of age, respectively, and did not give subsequent doses to infants beyond 24 weeks for Rotarix and 32 weeks for RotaTeq.33,34 There are no data from clinical trials on the use of rotavirus vaccines given outside the recommended dosing age ranges. While clinical trials excluded an association between Rotarix or RotaTeq and IS of the magnitude associated with RotaShield, post-marketing studies in Australia and in Mexico indicate that a smaller increase in the absolute risk of IS might exist, particularly post dose 1 (see 4.17.11 Adverse events below).56,57

Vaccine viruses replicate in the intestinal mucosa and can be shed in the stool of vaccine recipients, particularly after the 1st dose. Vaccine virus shedding is more common with Rotarix and is detected in the stool a week after vaccination in up to 80% of 1st dose recipients, and in up to 30% of 2nd dose recipients.58,59 RotaTeq is only shed after the 1st dose (in up to 13% of recipients).33 In one study of 80 sets of twins, transmission of Rotarix was observed to occur from 15 vaccinated infants to their unvaccinated twin,60 indicating that transmission of vaccine virus to unvaccinated contacts is likely to occur, but the clinical implication of this has not been studied (see 4.17.10 Precautions below).

Adventitious DNA fragments of porcine circoviruses have been detected in both Rotarix and RotaTeq vaccines. However, porcine circoviruses have never been shown to cause illness in humans and are considered non-pathogenic.

  • Rotarix – GlaxoSmithKline (live attenuated RIX4414 human rotavirus strain, type G1P1A[8]). Each 1.5 mL monodose pre-filled oral applicator or squeezable tube contains ≥106.0 cell culture infectious dose 50% (CCID50) of the RIX4414 strain; di-sodium adipate; Dulbecco’s Modified Eagle Medium; sterile water. Manufacture involves exposure to bovine-derived material.
  • RotaTeq – CSL Limited/Merck & Co Inc (live attenuated human–bovine reassortant rotavirus strains, types G1, G2, G3, G4 and P1A[8]). Each 2.0 mL monodose pre-filled dosing tube contains a minimum dose level of at least 2.0 x 106 infectious units of each of the rotavirus reassortants G1, G2, G3, G4 and P1A[8]; sodium citrate; sodium phosphate monobasic monohydrate; sodium hydroxide; polysorbate 80; cell culture medium. Manufacture involves exposure to bovine-derived material.

4.17.5 Transport, storage and handling

Transport according to National vaccine storage guidelines: Strive for 5.61 Store at +2°C to +8°C. Do not freeze. Protect from light.

4.17.6 Dosage and administration

Rotavirus vaccines are for oral administration only. Under no circumstances should rotavirus vaccines be injected.

Rotarix is recommended for use in a 2-dose course in infants and upper age limits apply; see Table 4.17.1. The liquid formulation is presented as a clear, colourless liquid contained within an oral applicator (syringe-type applicator with a plunger stopper or a squeezable tube). The 1.5 mL dose of vaccine should be administered orally from the oral applicator onto the inside of the infant’s cheek. Rotarix does not require reconstitution or dilution.

RotaTeq is recommended for use in a 3-dose course in infants and upper age limits apply; see Table 4.17.1. It is supplied in a container consisting of a squeezable plastic, latex-free dosing tube with a twist-off cap, allowing for direct oral administration of the 2 mL dose onto the inside of the infant’s cheek. RotaTeq does not require reconstitution or dilution. RotaTeq is a pale yellow, clear liquid that may have a pink tint.

There are limited data available on the safety of administering higher than the recommended dose of rotavirus vaccines or the efficacy of a partially administered dose(s). If most of an oral rotavirus vaccine dose has been spat out or vomited within minutes of administration, a single repeat dose can be administered during the same visit. If an infant regurgitates or vomits only a small part of a vaccine dose, it is not necessary to repeat the dose. Therefore, the regurgitated (and incomplete volume) dose is still considered as the valid dose.

Co-administration with other vaccines

Rotavirus vaccines can be co-administered with other vaccines included on the NIP schedule at 2 and 4 months of age (Rotarix) or 2, 4 and 6 months of age (RotaTeq). The available evidence from clinical trials suggests co-administration of oral rotavirus vaccines is safe and effective and does not interfere with the immune response to other vaccine antigens (DTPa, Hib, IPV, hepB, and pneumococcal conjugate vaccines).58,59,62

There are no restrictions on the timing of administration of any other live vaccines in relation to rotavirus vaccines, including BCG or oral poliomyelitis vaccine (OPV), for example, in infants who have received OPV overseas. Delay of rotavirus vaccination for 4 weeks following vaccination with BCG or vice versa is not necessary.

Interchangeability of rotavirus vaccines

Completion of a course of rotavirus vaccine should be with vaccine from the same manufacturer whenever possible. There are no studies that address the interchangeability of the two available rotavirus vaccines. However, if either dose 1 or 2 of vaccine is given as RotaTeq, a 3rd dose of either rotavirus vaccine should be given, provided that the upper age limit and inter-vaccine interval, as defined in Table 4.17.1, are met.

4.17.7 Recommendations


Administration of a course of oral rotavirus vaccination is recommended for all infants in the first half of the 1st year of life. Vaccination of older infants and children is not recommended as there are theoretical concerns regarding use in older age groups (see 4.17.4 Vaccines above). Vaccination should occur at either 2 and 4 months of age (Rotarix), or 2, 4 and 6 months of age (RotaTeq), according to the following schedules and upper age limits (see Table 4.17.1). The 1st dose of either rotavirus vaccine can be given as early as 6 weeks of age, where necessary (see Table 4.17.1). If the 1st dose is given at 6 weeks of age, the next scheduled rotavirus vaccine dose(s) should still be given according to the age limits specified for dosing in Table 4.17.1 below.

Rotarix (human monovalent rotavirus vaccine)

The vaccination course of Rotarix consists of 2 doses, at 2 and 4 months of age. The 1st dose should be given between 6 and 14 weeks of age (i.e. prior to turning 15 weeks old), and the 2nd dose should be given by 24 weeks of age (i.e. prior to turning 25 weeks old). The interval between the 2 doses should not be less than 4 weeks.

RotaTeq (pentavalent human–bovine reassortant rotavirus vaccine)

The vaccination course of RotaTeq consists of 3 doses, at 2, 4, and 6 months of age. The 1st dose should be given between 6 and 12 weeks of age (i.e. prior to turning 13 weeks old), and all doses should be given by 32 weeks of age (i.e. prior to turning 33 weeks old). The interval between doses should be at least 4 weeks.

Table 4.17.1: Upper age limits for dosing of oral rotavirus vaccines
  Doses Age of routine oral administration Recommended age limits for dosing - 1st dose Recommended age limits for dosing - 2nd dose Recommended age limits for dosing - 3rd dose Minimum interval between doses
2 oral doses (1.5 mL/dose) 2 and
4 months
6–14* weeks 10–24* weeks N/A 4 weeks
RotaTeq (CSL Limited/Merck
& Co Inc)
3 oral doses (2 mL/dose) 2, 4 and
6 months
6–12 weeks 10–32 weeks 14–32 weeks 4 weeks

* The upper age limit for receipt of the 1st dose of Rotarix is immediately prior to turning 15 weeks old, and the upper age limit for receipt of the 2nd dose is immediately prior to turning 25 weeks old.

† The upper age limit for receipt of the 1st dose of RotaTeq is immediately prior to turning 13 weeks old. The 2nd dose of vaccine should preferably be given by 28 weeks of age to allow for a minimum interval of 4 weeks before receipt of the 3rd dose. The upper age limit for the 3rd dose is immediately prior to turning 33 weeks old. For infants presenting for their 2nd dose after reaching 29 weeks of age, a 2nd and final dose can be given, provided the upper age limit of 32 weeks (immediately prior to turning 33 weeks old) has not been reached.

For infants in whom the 1st dose of rotavirus vaccine is inadvertently administered at an age greater than the suggested cut-off (i.e. after the 14th week of age for Rotarix or the 12th week of age for RotaTeq), the remaining vaccine doses should be administered as per the schedule, providing the minimum interval between doses can be maintained within the recommended age limits for subsequent doses. The timing of the 1st dose should not affect the safety and efficacy of the 2nd and 3rd doses.6 Infants who develop rotavirus gastroenteritis before receiving the full course of rotavirus vaccination should still complete the full 2- or 3-dose schedule (dependent on the brand of vaccine), because one rotavirus infection only provides partial immunity.6

Older infants

Vaccination of older infants, children or adults is not recommended. Infants should commence the course of rotavirus vaccination within the recommended age limits for the 1st dose and doses should not be given beyond the upper age limits for the final dose of the vaccine course (see ‘Infants’ above). The incidence of severe rotavirus infection decreases with increasing age and the benefit and safety profile of rotavirus vaccination in older infants and children has not been established.

Preterm infants

Vaccination of preterm infants using either rotavirus vaccine is indicated at a chronologic age (without correction for prematurity) of at least 6 weeks, if the infant is clinically stable. Preterm infants (born at <37 weeks gestation) appear to be at increased risk of hospitalisation from viral gastroenteritis.63 In clinical trials, RotaTeq or placebo was administered to 2070 preterm infants (25–36 weeks gestational age; median 34 weeks) who experienced rates of adverse events after vaccination similar to matched placebo recipients.6 Efficacy against rotavirus gastroenteritis of any severity appeared comparable to efficacy in full-term infants (73%; 95% CI: –2 to 95%).64 These conclusions would also be expected to apply to Rotarix vaccine, which appears safe and immunogenic in preterm infants.65 If standard infection control precautions are maintained, administration of rotavirus vaccine to hospitalised infants, including hospitalised preterm infants, would be expected to carry a low risk for transmission of vaccine viruses.

See also 4.17.10 Precautions below for other special risk groups and hospitalised infants.

4.17.8 Pregnancy and breastfeeding

There are no restrictions on the infant’s consumption of food or liquid, including breast milk, either before or after vaccination with either rotavirus vaccine.6,62

Infants living in households of pregnant women can receive rotavirus vaccines. Most pregnant women will have pre-existing immunity to rotavirus, but protection from transmission of wild-type infection through the vaccination of infant contacts may benefit adults, including pregnant women, and outweighs any theoretical concern regarding exposure to vaccine viruses.

4.17.9 Contraindications

The contraindications to rotavirus vaccines are:

  • anaphylaxis following a previous dose of either rotavirus vaccine
  • anaphylaxis following any vaccine component
  • previous history of intussusception or a congenital abnormality that may predispose to IS

The risk of recurrence of IS unrelated to rotavirus vaccination is in the order of 10%.66 In addition, certain congenital malformations affecting the gut (e.g. Meckel’s diverticulum) increase the risk of IS. Because of the possible association of rotavirus vaccination with an increased risk of IS (see 4.17.11 Adverse events below), it is considered prudent to withhold administration of rotavirus vaccines to an infant with a previous history of IS or with a known uncorrected congenital malformation associated with increased risk of IS.

  • severe combined immunodeficiency (SCID) in infants

Case reports from the United States67-69 indicate prolonged vaccine virus-associated gastrointestinal disease following receipt of rotavirus vaccines among infants with SCID. Because these infants are unlikely to generate a protective immune response to vaccination and because of potential harm, rotavirus vaccines are contraindicated for infants with SCID. For infants with less severe forms of immunocompromise, the risk of vaccine-associated disease is likely to be less than the risk of natural infection (see 4.17.10 Precautions below).

4.17.10 Precautions

Infants with acute gastroenteritis

Infants with moderate to severe acute gastroenteritis should not be vaccinated until after recovery from their acute illness. Infants with mild gastroenteritis (including mild diarrhoea) can be vaccinated. The use of rotavirus vaccines has not been studied in infants with acute gastroenteritis.

Infants with moderate to severe illness

As with other vaccines, infants with a moderate to severe illness should be vaccinated after recovery. In addition to the factors mentioned above, this avoids superimposing potential adverse events related to vaccination with the concurrent illness.

Infants with underlying conditions predisposing to severe rotavirus gastroenteritis

Conditions predisposing to severe or complicated rotavirus gastroenteritis include metabolic disorders and chronic gastrointestinal disease, such as Hirschsprung’s disease, malabsorption syndromes or short gut syndrome.1 Data on the safety of live rotavirus vaccines among such infants is limited. In one report, RotaTeq was reported to be tolerated in 8 of 9 infants with high-output ileostomies, while 1 infant experienced an increase in ileostomy losses.70 However, because of the greater risk of serious rotavirus disease, the benefits from vaccination are expected to outweigh the risk in these infants.

Infants who are immunocompromised

There are theoretical concerns that vaccine-associated gastrointestinal disease could occur in immunocompromised infants who receive rotavirus vaccines, and infants with the most severe forms of immunocompromise (SCID) should not receive rotavirus vaccine (see 4.17.9 Contraindications above). However, the risk for those infants with less severe immunocompromise may be less than the risk from natural infection. The risks and benefits of vaccination should be considered in the context of the infant’s specific immunocompromise with appropriate specialist advice6 (see 3.3.3 Vaccination of immunocompromised persons).

Rotavirus vaccines have been administered to HIV-infected infants in clinical trial settings.36-38 Specific data on the safety and efficacy of rotavirus vaccines in these infants are limited, but suggest that the vaccines are safe and immunogenic in HIV-infected, but clinically stable, children.71,72 (See also 3.3.3 Vaccination of immunocompromised persons and Table 3.3.4 Categories of immunocompromise in HIV-infected persons, based on age-specific CD4+ counts and percentage of total lymphocytes.) There are no data on the use of rotavirus vaccines in infants born to women who have received immunosuppressive therapy in pregnancy (see ‘Use of immunosuppressive therapy during pregnancy’ in 3.3.2 Vaccination of women who are planning pregnancy, pregnant or breastfeeding, and preterm infants).

Infants living in households with people who are immunocompromised

Infants living in households with immunocompromised persons should be vaccinated. In general, immunocompromised household members are afforded protection by vaccination of young children in the household and this is considered to outweigh the risk of transmitting vaccine virus shed in stools to the immunocompromised household member. However, there have been no studies to specifically address this question.6 Hand washing and the careful disposal of soiled nappies are likely to minimise any risk of vaccine transmission to other household members. (See also 3.3.3 Vaccination of immunocompromised persons.)

Recent administration of antibody-containing blood products

Infants who have recently received antibody-containing blood products and are at an eligible age should be vaccinated. The interval between vaccination and receipt of the blood product should be as long as possible, but without delaying administration of vaccine beyond the suggested age limits for dosing (as per Table 4.17.1 above). This recommendation for maximising the interval between receipt of antibody-containing blood products and rotavirus vaccination is based on theoretical concern that passively acquired antibody to rotavirus may interfere with vaccine immunogenicity.6

Hospitalised infants

Administration of rotavirus vaccine to hospitalised infants, including premature infants, is likely to carry a low risk for transmission of vaccine viruses if standard infection control precautions are maintained. Provided that the infant is medically stable, vaccination should not be delayed, particularly if the delay would result in an infant being beyond the upper age limit for vaccination (see 4.17.7 Recommendations above). If a recently vaccinated child is hospitalised for any reason, no precautions other than routine standard precautions need be taken to prevent the spread of vaccine virus in the hospital setting.

4.17.11 Adverse events


Although clinical trials of the two available vaccines did not find an association between vaccination and intussusception (IS)39 (see 4.17.4 Vaccines above), one post-marketing study in Australia found evidence of a 4- to 5-fold increase in the risk of IS in the 7 days following the 1st dose of either Rotarix or RotaTeq.56 However, no overall increase in the risk of IS was detectable over the first 9 months of life.56 A similar apparent increase in risk for IS following the 1st dose of Rotarix has been observed in Mexico, and a smaller increase after the 2nd dose of Rotarix in Brazil.57 A study in the United States found no increased risk of IS following RotaTeq; however, the study was limited by small numbers, which reduced power to determine a low range risk increase.73 A subsequent Australian study estimated the increased risk of IS to be approximately 9-fold in the first

7 days after dose 1, and 2-fold in the first 7 days after dose 2 of either vaccine.74 The baseline risk of intussusception for Australian infants is around 80 cases per 100 000 infants.75 The increased risk of IS following rotavirus vaccination, from the most recent Australian study, is estimated as approximately 6 additional cases of intussusception among every 100 000 infants vaccinated, or 14 additional cases per year in Australia.74 This estimate assumes that infants in which an episode of IS occurs shortly after vaccination would not have otherwise experienced a ‘natural’ episode of intussusception; however, this cannot be determined from current data. Importantly, studies from both Australia14-17 and overseas57 have demonstrated the substantial impact of vaccination in preventing rotavirus morbidity and mortality (see also 4.17.3 Epidemiology above). Rotavirus vaccines continue to be recommended for use on the basis of this positive benefit to risk profile.76 Immunisation providers should inform parents and carers of the rare risk of intussusception and how to be alert for the signs and symptoms of the condition.

Rotavirus vaccine should not be given to an infant who has had a confirmed intussusception because there may be an increased risk of the condition recurring (see 4.17.9 Contraindications above).

Other adverse events

No significant increase in post-vaccination vomiting, diarrhoea or fever has been reported during follow-up of several thousand recipients of Rotarix compared to those who were unvaccinated.39,77 Detailed follow-up of 11 700 recipients of RotaTeq or placebo reported no increase in fever or irritability in the week after vaccination among vaccinated infants, but a small increase in the incidence of vomiting (7% versus 5%) and diarrhoea (10% versus 9%).78 Vomiting and diarrhoea have not emerged as important adverse events following immunisation in post-marketing surveillance of rotavirus vaccines.

Infants who report an episode of diarrhoea or vomiting following vaccination should still receive subsequent rotavirus vaccine doses, as required and age eligible. The potential causes of diarrhoea/vomiting following vaccination include: gastroenteritis unrelated to rotavirus vaccination or infection (e.g. another viral agent); natural rotavirus infection (as vaccination is neither immediately protective nor 100% protective against all disease); or symptoms from vaccine virus replication (less likely). If rotavirus is detected by routine stool testing on a recently vaccinated infant, a positive test result can represent either natural infection or vaccine virus (as vaccine virus shedding occurs commonly after vaccination (see 4.17.4 Vaccines above). Specific testing is required to differentiate between vaccine virus and natural infection; however, this is rarely clinically indicated.

4.17.12 Variations from product information

The product information for Rotarix states that the vaccine should not be administered to subjects with any chronic gastrointestinal disease. The ATAGI recommends instead that pre-existing chronic gastrointestinal disease is not a contraindication to rotavirus vaccination, with the exception of those conditions that may predispose to IS (see 4.17.9 Contraindications and 4.17.10 Precautions above).

The product information for RotaTeq states that in the event that a dose of vaccine is spat out or vomited post vaccination, a replacement dose should not be given. The ATAGI recommends instead that if most of a dose is spat out or vomited then a single replacement dose may be given (see 4.17.6 Dosage and administration above.)


  1. Estes MK, Kapikian AZ. Rotaviruses. In: Knipe DM, Howley PM, Griffin DE, et al., eds. Fields virology. Philadelphia, PA: Lippincott, Williams and Wilkins, 2007.
  2. Cunliffe NA, Nakagomi O. A critical time for rotavirus vaccines: a review. Expert Review of Vaccines 2005;4:521-32.
  3. Bishop RF, Masendycz PJ, Bugg HC, Carlin JB, Barnes GL. Epidemiological patterns of rotaviruses causing severe gastroenteritis in young children throughout Australia from 1993 to 1996. Journal of Clinical Microbiology 2001;39:1085-91.
  4. Kirkwood CD, Bogdanovic-Sakran N, Cannan D, Bishop RF, Barnes GL. National Rotavirus Surveillance Program annual report, 2004–05. Communicable Diseases Intelligence 2006;30:133-6.
  5. Cunliffe NA, Bresee JS, Gentsch JR, Glass RI, Hart CA. The expanding diversity of rotaviruses. The Lancet 2002;359:640-2.
  6. Centers for Disease Control and Prevention (CDC), Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports 2006;55(RR-12):1-13.
  7. Butz AM, Fosarelli P, Dick J, Cusack T, Yolken R. Prevalence of rotavirus on high-risk fomites in day-care facilities. Pediatrics 1993;92:202-5.
  8. Dennehy PH, Nelson SM, Crowley BA, Saracen CL. Detection of rotavirus RNA in hospital air samples by polymerase chain reaction (PCR). [1998 abstract The American Pediatric Society and The Society for Pediatric Research]. Pediatric Research 1998;43 Suppl 2:143A.
  9. Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006;24:2718-31.
  10. Velázquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. New England Journal of Medicine 1996;335:1022-8.
  11. Galati JC, Harsley S, Richmond P, Carlin JB. The burden of rotavirus-related illness among young children on the Australian health care system. Australian and New Zealand Journal of Public Health 2006;30:416-21.
  12. Newall AT, MacIntyre R, Wang H, Hull B, Macartney K. Burden of severe rotavirus disease in Australia. Journal of Paediatrics and Child Health 2006;42:521-7.
  13. Carlin JB, Chondros P, Masendycz P, et al. Rotavirus infection and rates of hospitalisation for acute gastroenteritis in young children in Australia, 1993–1996. Medical Journal of Australia 1998;169:252-6.
  14. Buttery JP, Lambert SB, Grimwood K, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia’s national childhood vaccine schedule. [erratum appears in Pediatr Infect Dis J. 2011 Oct; 30(10):916]. Pediatric Infectious Disease Journal 2011;30(1 Suppl):S25-9.
  15. Macartney KK, Porwal M, Dalton D, et al. Decline in rotavirus hospitalisations following introduction of Australia’s national rotavirus immunisation programme. Journal of Paediatrics and Child Health 2011;47:266-70.
  16. Clarke MF, Davidson GP, Gold MS, Marshall HS. Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination. Vaccine 2011;29:4663-7.
  17. Dey A, Wang H, Menzies R, Macartney K. Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. Medical Journal of Australia 2012;197:453-7.
  18. Belshaw DA, Muscatello DJ, Ferson MJ, Nurkic A. Rotavirus vaccination one year on. Communicable Diseases Intelligence 2009;33:337-40.
  19. Lambert SB, Faux CE, Hall L, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. [erratum appears in Med J Aust. 2010 May 3;192(9):525]. Medical Journal of Australia 2009;191:157-60.
  20. Blumer C, Roche P, Kirkwood C, Bishop R, Barnes G. Surveillance of viral pathogens in Australia. Rotavirus. Communicable Diseases Intelligence 2003;27:496-503.
  21. Armstrong P. Rotaviral gastroenteritis in the NT: a description of the epidemiology 1995–2001 and future directions for research. The Northern Territory Disease Control Bulletin 2001;8(3):1-5.
  22. Williams G, Zerna L. Rotavirus outbreak in central Australia. Australian Infection Control 2002;7:51-8.
  23. Schultz R. Rotavirus gastroenteritis in the Northern Territory, 1995–2004. Medical Journal of Australia 2006;185:354-6.
  24. Saulsbury FT, Winkelstein JA, Yolken RH. Chronic rotavirus infection in immunodeficiency. Journal of Pediatrics 1980;97:61-5.
  25. Yolken RH, Bishop CA, Townsend TR, et al. Infectious gastroenteritis in bone-marrow-transplant recipients. New England Journal of Medicine 1982;306:1009-12.
  26. Fischer TK, Bresee JS, Glass RI. Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. Vaccine 2004;22 Suppl 1:S49-54.
  27. Frühwirth M, Heininger U, Ehlken B, et al. International variation in disease burden of rotavirus gastroenteritis in children with community- and nosocomially acquired infection. Pediatric Infectious Disease Journal 2001;20:784-91.
  28. Ringenbergs ML, Davidson GP, Spence J, Morris S. Prospective study of nosocomial rotavirus infection in a paediatric hospital. Australian Paediatric Journal 1989;25:156-60.
  29. Gleizes O, Desselberger U, Tatochenko V, et al. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatric Infectious Disease Journal 2006;25(1 Suppl):S12-21.
  30. Snelling T, Cripps T, Macartney K, et al. Nosocomial rotavirus infection in an Australian children’s hospital [letter]. Journal of Paediatrics and Child Health 2007;43:327.
  31. Anderson EJ, Weber SG. Rotavirus infection in adults. The Lancet Infectious Diseases 2004;4:91-9.
  32. Marshall J, Botes J, Gorrie G, et al. Rotavirus detection and characterisation in outbreaks of gastroenteritis in aged-care facilities. Journal of Clinical Virology 2003;28:331-40.
  33. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine 2006;354:23-33.
  34. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine 2006;354:11-22.
  35. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. The Lancet 2007;370:1757-63.
  36. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine 2010;362:289-98.
  37. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. The Lancet 2010;376:606-14.
  38. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. The Lancet 2010;376:615-23.
  39. Soares-Weiser K, MacLehose H, Bergman H, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews 2012;(2):CD008521. doi:10.1002/14651858.CD008521.pub2.
  40. Vesikari T, Giaquinto C, Huppertz HI. Clinical trials of rotavirus vaccines in Europe. Pediatric Infectious Disease Journal 2006;25:S42-7.
  41. Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal 2010;29:957-63.
  42. Field EJ, Vally H, Grimwood K, Lambert SB. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010;126:e506-12.
  43. Curns AT, Steiner CA, Barrett M, et al. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. Journal of Infectious Diseases 2010;201:1617-24.
  44. Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010;125:e208-13.
  45. Cortese MM, Tate JE, Simonsen L, Edelman L, Parashar UD. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatric Infectious Disease Journal 2010;29:489-94.
  46. Snelling TL, Schultz R, Graham J, et al. Rotavirus and the Indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clinical Infectious Diseases 2009;49:428-31.
  47. World Health Organization (WHO). Meeting of the immunization Strategic Advisory Group of Experts, April 2009 – conclusions and recommendations. Weekly Epidemiological Record 2009;84:220-36.
  48. Lanzieri TM, Linhares AC, Costa I, et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. International Journal of Infectious Diseases 2011;15:e206-10.
  49. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. New England Journal of Medicine 2010;362:299-305.
  50. Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in Central Australia. Clinical Infectious Diseases 2011;52:191-9.
  51. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. [erratum appears in N Engl J Med 2001 May 17;344(20):1564]. New England Journal of Medicine 2001;344:564-72.
  52. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on RotaShield and intussusception: the role of age at the time of vaccination. Journal of Infectious Diseases 2005;192 Suppl 1:S36-43.
  53. Kapikian AZ, Hoshino Y, Chanock RM, Pérez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. Journal of Infectious Diseases 1996;174 Suppl 1:S65-72.
  54. Pérez-Schael I, Guntiñas MJ, Pérez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. [erratum appears in N Engl J Med 1998 Apr 2;338(14):1002]. New England Journal of Medicine 1997;337:1181-7.
  55. Haber P, Chen RT, Zanardi LR, et al. An analysis of rotavirus vaccine reports to the Vaccine Adverse Event Reporting System: more than intussusception alone? Pediatrics 2004;113:e353-9.
  56. Buttery JP, Danchin MH, Lee KJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011;29:3061-6.
  57. Patel MM, López-Collada VR, Bulhões MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. New England Journal of Medicine 2011;364:2283-92.
  58. Phua KB, Quak SH, Lee BW, et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases 2005;192 Suppl 1:S6-16.
  59. Salinas B, Pérez-Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal 2005;24:807-16.
  60. GlaxoSmithKline. A study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family ( Identifier: NCT00396630). 2009. Available at: (accessed Apr 2011).
  61. National vaccine storage guidelines: Strive for 5. 2nd ed. Canberra: Australian Government Department of Health and Ageing, 2013. Available at: ( (accessed Nov 2013).
  62. Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatric Infectious Disease Journal 2005;24:481-8.
  63. Newman RD, Grupp-Phelan J, Shay DK, Davis RL. Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics 1999;103:e3.
  64. Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal 2007;26:1099-104.
  65. Omenaca F, Sarlangue J, Szenborn L, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatric Infectious Disease Journal 2012;31:487-93.
  66. Daneman A, Alton DJ, Lobo E, et al. Patterns of recurrence of intussusception in children: a 17-year review. Pediatric Radiology 1998;28:913-9.
  67. Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. New England Journal of Medicine 2010;362:314-9.
  68. Bakare N, Menschik D, Tiernan R, Hua W, Martin D. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine 2010;28:6609-12.
  69. Werther RL, Crawford NW, Boniface K, Kirkwood CD, Smart JM. Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency [letter]. Journal of Allergy and Clinical Immunology 2009;124:600.
  70. Fang AY, Tingay DG. Early observations in the use of oral rotavirus vaccination in infants with functional short gut syndrome. Journal of Paediatrics and Child Health 2011;48:512-6.
  71. Steele AD, Cunliffe N, Tumbo J, et al. A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children. Journal of Infectious Diseases 2009;200 Suppl 1:S57-62.
  72. Steele AD, Madhi SA, Louw CE, et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatric Infectious Disease Journal 2011;30:125-30.
  73. Shui IM, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA 2012;307:598-604.
  74. Carlin JB, Macartney KK, Lee KJ, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's national immunization program. Clinical Infectious Diseases 2013;57:1427-34.
  75. Justice F, Carlin J, Bines J. Changing epidemiology of intussusception in Australia. Journal of Paediatrics and Child Health 2005;41:475-8.
  76. Bishop J. CMO letter on intussusception and rotavirus vaccine. 25 February 2011. Available at: (accessed Apr 2012).
  77. Cheuvart B, Friedland LR, Abu-Elyazeed R, et al. The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability. Pediatric Infectious Disease Journal 2009;28:225-32.
  78. Dennehy PH, Goveia MG, Dallas MJ, Heaton PM. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases 2007;11 Suppl 2:S36-42.